This is an old revision of this page, as edited by Vanisaac (talk | contribs) at 22:43, 12 July 2014 (template:Pmid -> template:Cite pmid per Misplaced Pages:Redirects for discussion/Log/2014 July 2#Template:Pmid, replaced: {{pmid → {{cite pmid using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 22:43, 12 July 2014 by Vanisaac (talk | contribs) (template:Pmid -> template:Cite pmid per Misplaced Pages:Redirects for discussion/Log/2014 July 2#Template:Pmid, replaced: {{pmid → {{cite pmid using AWB)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compoundClinical data | |
---|---|
Trade names | Marquis |
AHFS/Drugs.com | FDA Professional Drug Information |
Routes of administration | Oral |
ATCvet code | |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.157.907 |
Chemical and physical data | |
Formula | C18H14F3N3O6S |
Molar mass | 457.380 g/mol g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
Ponazuril (INN), sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by Sarcocystis neurona. More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats and dogs against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.
See also
References
- Marquis FDA Professional Drug Information
- Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 18312139, please use {{cite journal}} with
|pmid=18312139
instead.
This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it. |
This veterinary medicine–related article is a stub. You can help Misplaced Pages by expanding it. |